Novo Settled NovoSeven Case to Avoid Long Court Battle, CEO Says
This article is for subscribers only.
Novo Nordisk A/S settled drug marketing allegations this month to avoid a court battle with the U.S. government and can’t guarantee such charges won’t arise again, Chief Executive Officer Lars Rebien Soerensen said.
“We still maintain that we have done nothing wrong but a potential lawsuit with the government would be lengthy and costly and, considering the amount we would settle for, not in the interest of the company,” Soerensen said today by phone.